Welcome to our dedicated page for Destra Multi-Alternative SEC filings (Ticker: DMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Destra Multi-Alternative Fund (NYSE: DMA) files a range of documents with the U.S. Securities and Exchange Commission as a non-diversified, closed-end management investment company. These SEC filings provide detailed insight into the fund’s governance, policies, and operations, complementing its stated objective of seeking capital appreciation and income with an emphasis on income generation and long-term, non-correlated performance.
Among the key filings are proxy statements on Schedule 14A (DEF 14A), which describe matters submitted to stockholders, such as the election of trustees and changes to fundamental investment policies. Recent definitive proxy statements explain the fund’s proposal to revise its fundamental policy regarding industry concentration, eliminating the requirement to invest over 25% of net assets in the real estate industry. These documents outline the Board of Trustees’ rationale, the role of Destra Capital Advisors LLC and Validex Global Investing, and the voting process for stockholders.
The fund also files current reports on Form 8-K to disclose material events. One such filing reports the results of a special meeting of shareholders where the proposal to revise the concentration policy received the requisite votes for adoption. The 8-K identifies the fund’s common shares registered under Section 12(b) of the Securities Exchange Act of 1934, trading under the symbol DMA on the New York Stock Exchange, and provides the detailed vote counts on the proposal.
On this SEC filings page, users can review these and other regulatory documents, including materials related to the fund’s Amended and Restated Declaration of Trust, term structure, and governance. Stock Titan enhances access to these filings with AI-powered summaries that explain complex sections in straightforward language, highlight the implications of policy changes, and help readers understand how board decisions, proxy proposals, and material events relate to the fund’s alternative investment strategy. Investors can use this resource to follow DMA’s regulatory history, board actions, and shareholder approvals as documented in its official SEC submissions.
Schedule 13D/A Amendment No. 12 discloses that Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein (together, the Reporting Persons) beneficially own 2,235,144 common shares of Destra Multi-Alternative Fund (ticker DMA), representing 24.94% of the 8,963,239 shares outstanding as of March 31, 2025. The Reporting Persons report shared voting and dispositive power over these shares and state approximately $15,109,969 was paid to acquire the reported position, funded from investor subscription proceeds, capital appreciation and margin borrowings. No new purpose for the holdings is reported and no contracts or arrangements concerning the securities are disclosed. Recent open-market transactions from the prior 8/18/25 filing through 9/9/25 are referenced and incorporated by Schedule A.
Destra Multi-Alternative Fund (DMA) Form 4 shows Saba Capital Management, L.P. and individual Boaz Weinstein reported an insider purchase on 09/08/2025. The filing records an acquisition of 500 shares of Destra common stock at $8.58 per share, increasing reported indirect holdings to 2,166,695 shares. The reporting entities are identified as a director and a 10% owner of the issuer. The form is signed 09/09/2025.
Destra Multi-Alternative Fund (DMA) insiders reported an insider purchase on 09/05/2025. Saba Capital Management, L.P. and Boaz Weinstein disclosed acquisition of 27,923 shares of DMA common stock at $8.57 per share under transaction code P (purchase). After the reported transaction, the filing shows 2,166,195 shares beneficially owned indirectly by the reporting person(s).
Saba Capital Management and related persons report owning 2,138,272 common shares of Destra Multi-Alternative Fund, representing 23.86% of the outstanding shares based on 8,963,239 shares outstanding as of 3/31/25. This filing is Amendment No. 11 and updates Items 3, 5, and 7 of their Schedule 13D/A. The reporting persons state approximately $14,277,437 was paid to acquire the reported shares, with funds derived from investor subscriptions, capital appreciation and margin borrowings. The filing lists shared voting and dispositive power for the reporting persons and references Schedule A for open-market transactions between 7/30/25 and 8/14/25.
Saba Capital Management and individual Boaz Weinstein reported purchases of Destra Multi-Alternative Fund (DMA) common stock on 08/14/2025. The filing shows an acquisition of 41,802 shares at a price of $8.66 per share, increasing reported indirect beneficial ownership to 2,138,272 shares. The report lists the reporting parties as a director and a 10% owner and is filed jointly by more than one reporting person.
Saba Capital Management, L.P., its GP and founder Boaz R. Weinstein have filed Amendment No. 10 to their Schedule 13D on Destra Multi-Alternative Fund (CUSIP 25065A502). The filing, triggered by events on 07/28/2025, updates Items 3, 5 and 7.
- Beneficial ownership: 2,034,481 common shares, equal to 22.7 % of the outstanding 8,963,239 shares (per the fund’s 3/31/25 N-CSR).
- Voting/Dispositive power: 0 sole, 2,034,481 shared for both voting and disposition.
- Cost basis: Approximately $846,974 in aggregate, funded through investor capital, appreciation and ordinary-course margin borrowings.
- Reporting persons: Saba Capital Management, L.P.; Saba Capital Management GP, LLC; and Mr. Boaz R. Weinstein. Business address for all: 405 Lexington Ave., 58th Floor, New York, NY 10174.
- Purpose of amendment: provide updated ownership (Item 5), funding details (Item 3) and exhibit list (Item 7). No changes to criminal or civil backgrounds—none reported in past five years.
The stake was accumulated via open-market transactions between 5/12/25 and 7/28/25; detailed trade data appear in Exhibit 3 (Schedule A). Funds and accounts advised by Saba receive any dividends or sale proceeds.
Implication: With nearly a quarter of shares, Saba Capital is now a significant stakeholder capable of influencing future corporate actions of the closed-end fund.